[1]陈丛,闫明,宋艳萍.康柏西普对病理性近视脉络膜新生血管的疗效及视力预后相关性研究[J].眼科新进展,2020,40(6):569-573.[doi:10.13389/j.cnki.rao.2020.0131]
　CHEN Cong,YAN Ming,SONG Yanping.Efficacy of Conbercept for treatment of choroidal neovascularization with pathologic myopia and on visual prognosis[J].Recent Advances in Ophthalmology,2020,40(6):569-573.[doi:10.13389/j.cnki.rao.2020.0131]
点击复制

康柏西普对病理性近视脉络膜新生血管的疗效及视力预后相关性研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年6期
页码:
569-573
栏目:
应用研究
出版日期:
2020-06-05

文章信息/Info

Title:
Efficacy of Conbercept for treatment of choroidal neovascularization with pathologic myopia and on visual prognosis
作者:
陈丛; 闫明; 宋艳萍
510080　广东省广州市，南方医科大学第一临床医学院（陈丛，宋艳萍）；430070　湖北省武汉市，中国人民解放军中部战区总医院眼科，全军眼科中心（陈丛，闫明，宋艳萍）
Author(s):
CHEN Cong1; 2; YAN Ming2; SONG Yanping1; 2
1.The First School of Clinical Medicine,Southern Medical University,Guangzhou 510080,Guangdong Province,China
2.The Ophthalmology Center,General Hospital of Central Theater Command,Wuhan 430070,Hubei Province,China
关键词:
康柏西普; 病理性近视; 脉络膜新生血管; 最佳矫正视力; 荧光素眼底血管造影
Keywords:
Conbercept;  pathological myopia;  choroidal neovascularization;  best corrected visual acuity;  fundus fluorescein angiography
分类号:
R773.4
DOI:
10.13389/j.cnki.rao.2020.0131
文献标志码:
A
摘要:
目的　观察和评估康柏西普治疗病理性近视脉络膜新生血管（CNV）的有效性和安全性，探讨影响视力预后和玻璃体内注药次数的相关因素。方法　回顾性病例研究。临床检查确诊的病理性近视CNV患者47例49眼纳入研究。其中，男12例13眼，女35例36眼。年龄(56.67±13.90)岁，屈光度(-13.64±3.92)D，眼轴长度(29.03±1.36)mm。患者均为首次治疗，采用1+PRN的治疗方案给予所有患眼玻璃体内注射康柏西普0.05 mL(含康柏西普0.5 mg)治疗。均行最佳矫正视力(BCVA)、眼底彩色照相、荧光素眼底血管造影（FFA）、光学相干断层扫描(OCT)检查。BCVA检查采用国际标准视力表，记录时换算为最小分辨角对数(logMAR)视力。所有患眼随访时间超过24个月。观察并记录患眼治疗后1个月、3个月、6个月、12个月、24个月BCVA、黄斑中心凹视网膜厚度（CMT）、CNV面积、CNV渗漏面积变化及玻璃体内注药次数；将治疗后24个月logMAR BCVA及总注射针数分别与各基线资料（屈光度、眼轴、病理性近视分期、CNV位置、logMAR BCVA、CMT、CNV面积、CNV渗漏面积）进行Person或Spearman相关分析。结果　在24个月随访期内，患眼第1年与第2年平均注射针数分别为（3.51±1.54）次、（0.57±1.02）次，总注射针数为（4.08±1.75）次。与治疗前相比，治疗后1个月、3个月、6个月、12个月、24个月患眼BCVA明显提高，差异均有统计学意义（均为P＜0.05）。与治疗前相比，治疗后1个月、3个月、6个月、12个月、24个月患眼CMT明显下降，差异均有统计学意义（均为P＜0.05）。与治疗前相比，治疗后3个月、6个月、12个月、24个月患眼CNV面积明显下降，差异均有统计学意义（均为P＜0.05）。与治疗前相比，治疗后3个月、6个月、12个月、24个月患眼CNV渗漏面积明显下降，差异均有统计学意义（均为P＜0.05）。相关性分析结果显示，治疗后24个月logMAR BCVA与基线屈光度、眼轴、病理性近视分期、CNV位置、CMT、CNV面积均无明显相关(均为P>0.05)，但与基线logMAR BCVA、CNV渗漏面积呈正相关(r=0.595、0.319，P=0.000、0.026)。总注射针数与基线屈光度、眼轴、病理性近视分期、CNV位置、CNV面积均无明显相关(均为P>0.05)，但与基线CMT、CNV面积、CNV渗漏面积呈正相关(r=0.297、0.440、0.433，P=0.038、0.002、0.002)。所有患者均未出现眼部并发症以及全身不良反应。结论　康柏西普治疗病理性近视CNV可以带来较好的视力与解剖形态收益，效果安全有效；末次随访BCVA与基线BCVA、CNV渗漏面积具有正相关性，总注射针数与基线CMT、CNV面积、CNV渗漏面积具有正相关性。
Abstract:
Objective　To observe and evaluate the efficacy and safety of Conbercept for the treatment of pathological myopia (PM) with choroidal neovascularization (CNV), and to explore the factors affecting visual prognosis and the number of intravitreal injections. Methods　A retrospective case study was conducted on 49 eyes of 47 CNV patients with PM diagnosed by clinical examination. There were 13 eyes of 12 males and 36 eyes of 35 females, with average age of (56.67±13.90) years, mean diopter of (-13.64±3.92) D, and average axial length of (29.03±1.36) mm. All patients were treated for the first time, and received 1+PRN for intravitreal injection of 0.05 mL Conbercept (containing 0.5 mg Conbercept). Best corrected visual acuity (BCVA) detection, fundus color photography, fundus fluorescein angiography (FFA) and optical coherence tomography (OCT) were performed. BCVA was detected with international standard visual acuity chart and converted to the minimum resolution logarithm (logMAR) visual acuity. All affected eyes were followed up for more than 24 months to observe and record BCVA, central macular thickness (CMT), CNV area, CNV leakage area and number of intravitreal injections at 1, 3, 6, 12 and 24 months after treatment; for 24 months after treatment, correlation analysis was respectively conducted on logMAR BCVA and total number of intravitreal injections with baseline data (diopter, eye axis, PM stage, CNV location, logMAR BCVA, CMT, CNV area, area of CNV leakage) by Person or Spearman correlation analysis. Results　During the 24-month follow-up period, the average number of injections was 3.51±1.54 in the first year, and 0.57±1.02 in the second year, and the total number was 4.08±1.75. Compared with before treatment, BCVA was significantly increased in the affected eyes at 1, 3, 6, 12 and 24 months after treatment, and the differences were statistically significant (all P<0.05). Compared with before treatment, CMT of the affected eyes decreased significantly at 1, 3, 6, 12 and 24 months after treatment, and the differences were statistically significant (all P<0.05). Compared with before treatment, both CNV areas and CNV leakage areas of the affected eyes decreased significantly at 3, 6, 12 and 24 months after treatment, and the differences were statistically significant (all P<0.05). Correlation analysis showed that logMAR BCVA at 24 months after treatment had no significant correlation with diopter, axial length, PM stage, CNV location, CMT, CNV area at baseline (all P>0.05); but had positive correlation with baseline logMAR BCVA and CNV leakage area (r=0.595, 0.319; P=0.000, 0.026). The total number of injections had no significant correlation with diopter, axial length, PM stage, CNV location and CNV area at baseline (all P>0.05); but positive correlation with baseline CMT, CNV area and area of CNV leakage (r=0.297, 0.440, 0.433; P=0.038, 0.002, 0.002). All patients had no ocular complications or systemic adverse reactions. Conclusion　Conbercept is safe and effective for the treatment of PM with CNV and can achieve better vision benefit and anatomical benefit. The last follow-up BCVA has positive correlation with baseline BCVA and CNV leakage area, and the total number of injections has positive correlation with baseline CMT, CNV area and CNV leakage area.

参考文献/References:

［1］　OHNO-MATSUI K,LAI T Y,LAI C C,CHEUNG C M.Updates of pathologic myopia［J］.Prog Retin Eye Res,2016,52:156-187.
［2］　CHEUNG C,ARNOLD J J,HOLZ F G,PARK K H,LAI T,LARSEN M,et al.Myopic choroidal neovascularization:Review,guidance,and consensus statement on management［J］.Ophthalmology,2017,124(11):1690-1711.
［3］　ZHU Y,ZHANG T,XU G,PENG L.Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia［J］.Cochrane Database Syst Rev,2016,12（12）:CD011160.
［4］　WU Z,ZHOU P,LI X,WANG H,LUO D,QIAO H,et al.Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling［J］.PLoS ONE,2013,8(3):e57642.
［5］　ZHANG M,YU D,YANG C,XIA Q,LI W,LIU B,et al.The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization［J］.Pharm Res,2009,26(1):204-210.
［6］　ZHANG M,ZHANG J,YAN M,LUO D,ZHU W,KAISER P K,et al.A phase 1 study of KH902,a vascular endothelial growth factor receptor decoy,for exudative age-related macular degeneration［J］.Ophthalmology,2011,118(4):672-678.
［7］　WOLF S,BALCIUNIENE V J,LAGANOVSKA G,MENCHINI U,OHNO-MATSUI K,SHARMA T,et al.RADIANCE:a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia［J］.Ophthalmology,2014,121(3):682-692.
［8］　OHNO-MATSUI K,KAWASAKI R,JONAS J B,CHEUNG C M,SAW S M,VERHOEVEN V J,et al.International photographic classification and grading system for myopic maculopathy［J］.Am J Ophthalmol,2015,159(5):877-883.
［9］　YOSHIDA T,OHNO-MATSUI K,YASUZUMI K,KOJIMA A,SHIMADA N,FUTAGAMI S,et al.Myopic choroidal neovascularization:a 10-year follow-up［J］.Ophthalmology,2003,110(7):1297-1305.
［10］　WANG E,CHEN Y.Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia:systematic review and meta-analysis［J］.Retina,2013,33(7):1375-1392.
［11］　ZHANG M,ZHANG J,YAN M,LUO D,ZHU W,KAISER P K,et al.A phase 1 study of KH902,a vascular endothelial growth factor receptor decoy,for exudative age-related macular degeneration［J］.Ophthalmology,2011,118(4):672-678.
［12］　LI X,XU G,WANG Y,XU X,LIU X,TANG S,et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration［J］.Ophthalmology,2014,121(9):1740-1747.
［13］　YAN M,HUANG Z,LIAN H Y,SONG Y P,CHEN X.Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia［J］.Acta Ophthalmol,2019，97(5):e813-e814.
［14］　IKUNO Y,OHNO-MATSUI K,WONG T Y,KOROBELNIK J,VITTI R,LI T,et al.Intravitreal aflibercept injection in patients with myopic choroidal neovascularization［J］.Ophthalmology,2015,122(6):1220-1227.
［15］　IACONO P,PARODI M B,SELVI F,PARRAVANO M C,CHIARAVALLOTI A,VARANO M,et al.Factors influencing visual acuity in patients receiving anti-vascular endothelial growth factor for myopic choroidal neovascularization ［J］.Retina,2017,37(10):1931-1941.
［16］　BATTAGLIA P M,IACONO P,ROMANO F,BANDELLO F.Fluorescein leakage and optical coherence tomography features of choroidal neovascularization secondary to pathologic myopia［J］.Invest Ophthalmol Vis Sci,2018,59(7):3175-3180.

相似文献/References:

[1]金昱 石安娜 刘维锋 石浔 王永波.频域OCT在光动力疗法治疗病理性近视脉络膜新生血管中的应用[J].眼科新进展,2012,32(10):000.
[2]黄志坚 宋艳萍 金中秋 丁琴 陈中山.光动力疗法联合玻璃体内注射Bevacizumab治疗病理性近视合并脉络膜新生血管[J].眼科新进展,2013,33(4):000.
[3]王晓霞 史志洁 林娜 刘晓瑞.光学相干断层扫描在病理性近视黄斑裂孔中的应用[J].眼科新进展,2013,33(9):000.
[4]陆秉文,吴星伟. Ranibizumab玻璃体内注射治疗病理性近视脉络膜新生血管研究进展[J].眼科新进展,2014,34(9):897.[doi:10.13389/j.cnki.rao.2014.0248]
[5]丁雯芝,邹俊.病理性近视脉络膜新生血管发病机制的研究进展[J].眼科新进展,2014,34(10):987.[doi:10.13389/j.cnki.rao.2014.0274]
[6]陈珊娜,郑丽梅,洪荣照,等. 饼式后巩膜加固术治疗未成年人病理性近视临床研究[J].眼科新进展,2015,35(4):351.[doi:10.13389/j.cnki.rao.2015.0094]
　CHEN Shan-Na,ZHENG Li-Mei,HONG Rong-Zhao,et al. Clinical observation of cake-type sclera reinforcement for pathological myopia in minor[J].Recent Advances in Ophthalmology,2015,35(6):351.[doi:10.13389/j.cnki.rao.2015.0094]
[7]田楠楠,亢泽峰,张庆.加减驻景方对病理性近视脉络膜新生血管动物模型血管内皮生长因子及色素上皮衍生因子表达的影响[J].眼科新进展,2015,35(10):906.[doi:10.13389/j.cnki.rao.2015.0247]
　TIAN Nan-Nan,KANG Ze-Feng,ZHANG Qing.Effects of modified Zhu Jing prescriptions on expression of VEGF and PEDF in pathologic myopia with choroidal neovascularization animal model[J].Recent Advances in Ophthalmology,2015,35(6):906.[doi:10.13389/j.cnki.rao.2015.0247]
[8]修立恒,李佳林,李常栋,等.玻璃体内注射雷珠单抗治疗病理性近视合并脉络膜新生血管疗效观察[J].眼科新进展,2015,35(11):1067.[doi:10.13389/j.cnki.rao.2015.0292]
　XIU Li-Heng,LI Jia-Lin,LI Chang-Dong,et al.Pathological myopia combined with choroidal neovascularization treated by intravitreal injection of ranibizumab[J].Recent Advances in Ophthalmology,2015,35(6):1067.[doi:10.13389/j.cnki.rao.2015.0292]
[9]张娣,张玲,杨静,等.玻璃体内注射康柏西普联合手术及全视网膜光凝治疗新生血管性青光眼[J].眼科新进展,2015,35(12):1170.[doi:10.13389/j.cnki.rao.2015.0320]
　ZHANG Di,ZHANG Ling,YANG Jing,et al.Intravitreal injection of conbercept combined with operation and panretinal photocoagulation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(6):1170.[doi:10.13389/j.cnki.rao.2015.0320]
[10]李娜,张杰,高荣玉,等.单次注射康柏西普治疗渗出型AMD患者RPE隆起面积与容积变化[J].眼科新进展,2016,36(2):172.[doi:10.13389/j.cnki.rao.2016.0047]
　LI Na,ZHANG Jie,GAO Rong-Yu,et al.Changes of retinal pigment epithelium uplift area and volume in exudative age-related macular degeneration after once injection of conbercept[J].Recent Advances in Ophthalmology,2016,36(6):172.[doi:10.13389/j.cnki.rao.2016.0047]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2020-06-05